A Phase 4 interventional study of sumatriptan and naproxen sodium combination tablet and sumatriptan tablet in Migraine Disorders, sponsored by GlaxoSmithKline. Completed at 49 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-23.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Migraine Disorders by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Migraine Disorders · GlaxoSmithKline.
Among the 28 studies in Migraine Disorders by GlaxoSmithKline, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2008, is the only one in phase 4, and was the 16th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 341 are open to participants now.
Browse Migraine Disorders studies →None of the 28 studies in Migraine Disorders by GlaxoSmithKline is open now. The open studies under Migraine Disorders, anywhere →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 407 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 320 across the 19 interventional studies, 500 across the 9 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Migraine Disorders by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects eligible for enrollment in the study must meet all of the following criteria:
Male and female outpatients 18 to 65 years of age. Female subjects are eligible for participation in the study if they are:
Exclusion criteria:
Subjects meeting any of the following criteria must not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sumatriptan and naproxen sodium combination tablet
Drug: sumatriptan tablet
Drug: naproxen sodium tablet
sumatriptan 85mg and naproxen sodium 500mg
sumatriptan 85mg
Naproxen sodium 500mg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen
The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
Time frame: Baseline and Month 6
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
Time frame: Baseline and Month 6
Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
Time frame: Baseline and Month 6
Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Naproxen
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
Time frame: Baseline and Month 6
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <4 Migraines, 4-6 Migraines, >=4 Migraines, and >6 Migraines Per Month
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for \> 6 migraines/month group due to lack of convergence.
Time frame: Baseline and Month 6
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, <1.3 Times Per Migraine, 1.3-1.7 Times Per Migraine, and >1.7 Times Per Migraine
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis.
Time frame: Baseline and Month 6
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating, on Average, With <6, 6-10, >=6, 10-14, and >14 Doses Per Month
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 10-14 and the \>14 doses/month groups due to lack of convergence.
Time frame: Baseline and Month 6
Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen for the ITT Subpopulation of Participants Treating With <30 Total Doses, 30-60 Total Doses, >=30, 60-90 Total Doses, and >90 Total Doses
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the \>90 total dose groups due to lack of convergence.
Time frame: Baseline and Month 6
Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
The number of participants with an increase of \>=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements
The number of participants with an increase of \>=3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study
The number of participants with any valid two-day consecutive average systolic blood pressure measurement of \>=140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg
The number of participants with any valid two-day consecutive average diastolic blood pressure measurement of \>=90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
Time frame: Baseline to End of Study (6-month study duration)
Number of Participants Withdrawn From the Study Due to Blood Pressure Changes
The number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or \>=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of \>=30 mmHg systolic or \>=20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic \>=140 mmHg or diastolic \>=90 mmHg on consecutive clinic visits \>=2 weeks apart.
Time frame: Baseline to End of Study (6-month study duration)
| Milestone | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Started | 135 | 136 | 136 |
| Completed | 67 | 55 | 55 |
| Not completed | 68 | 81 | 81 |
| Withdrew: Protocol violation | 17 | 23 | 20 |
| Withdrew: Met protocol-defined stopping criteria | 19 | 20 | 20 |
| Withdrew: Lost to follow-up | 13 | 19 | 14 |
| Withdrew: Withdrew consent | 10 | 13 | 9 |
| Withdrew: Lack of efficacy | 3 | 4 | 13 |
| Withdrew: Adverse event | 4 | 2 | 3 |
| Withdrew: Investigator discretion | 2 | 0 | 2 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
| mmHg | Sumatriptan | Naproxen |
|---|---|---|
| Systolic, Baseline, n=109, 115 | 110.8 ± 9.15 | 110.1 ± 9.19 |
| Systolic, Month 6, n=42, 37 | 109.4 ± 7.70 | 108.2 ± 9.16 |
| Systolic, Change from Baseline, n=41, 36 | -2.8 ± 5.69 | -1.8 ± 6.53 |
| Diastolic, Baseline, n=109, 115 | 75.7 ± 7.38 | 74.7 ± 7.00 |
| Diastolic, Month 6, n=42, 37 | 73.9 ± 7.03 | 74.3 ± 8.47 |
| Diastolic, Change from Baseline, n=41, 36 | -1.6 ± 4.21 | -0.6 ± 5.50 |
The calculation of baseline and post-baseline mean blood pressure (BP) (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
| millimeters of mercury (mmHg) | Sumatriptan/Naproxen |
|---|---|
| Systolic, Baseline, n=120 | 111.7 ± 9.00 |
| Systolic, Month 6, n=48 | 107.1 ± 9.59 |
| Systolic, Change from Baseline, n=47 | -2.9 ± 5.24 |
| Diastolic, Baseline, n=120 | 76.0 ± 6.83 |
| Diastolic, Month 6, n=48 | 73.0 ± 6.84 |
| Diastolic, Change from Baseline, n=47 | -2.1 ± 4.44 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
| mmHg | Sumatriptan/Naproxen | Sumatriptan |
|---|---|---|
| Systolic, Baseline, n=120, 109 | 111.7 ± 9.00 | 110.8 ± 9.15 |
| Systolic, Month 6, n=48, 42 | 107.1 ± 9.59 | 109.4 ± 7.70 |
| Systolic, Change from Baseline, n=47, 41 | -2.9 ± 5.24 | -2.8 ± 5.69 |
| Diastolic, Baseline, n=120, 109 | 76.0 ± 6.83 | 75.7 ± 7.38 |
| Diastolic, Month 6, n=48, 42 | 73.0 ± 6.84 | 73.9 ± 7.03 |
| Diastolic, Change from Baseline, n=47, 41 | -2.1 ± 4.44 | -1.6 ± 4.21 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid Telephonic Self-Measured Blood Pressure (T-SMBP) measurements. T-SMBP technology is a method that allows the participant to self-measure BP outside the clinic using a BP monitor and transfer the data from their home to a central server. Change from baseline was calculated as the Month 6 value minus the Baseline value. Least squares mean and confidence intervals were based on mixed model repeated measures analysis (MMRM).
| mmHg | Sumatriptan/Naproxen | Naproxen |
|---|---|---|
| Systolic, Baseline, n=120, 115 | 111.7 ± 9.00 | 110.1 ± 9.19 |
| Systolic, Month 6, n=48, 37 | 107.1 ± 9.59 | 108.2 ± 9.16 |
| Systolic, Change from Baseline, n=47, 36 | -2.9 ± 5.24 | -1.8 ± 6.53 |
| Diastolic, Baseline, n=120, 115 | 76.0 ± 6.83 | 74.7 ± 7.00 |
| Diastolic, Month 6, n=48, 37 | 73.0 ± 6.84 | 74.3 ± 8.47 |
| Diastolic, Change from Baseline, n=47, 36 | -2.1 ± 4.44 | -0.6 ± 5.50 |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis. LSMeans and corresponding confidence intervals were not calculated for \> 6 migraines/month group due to lack of convergence.
| mmHg | Sumatriptan/Naproxen |
|---|---|
| Systolic, <4 migraines per month | -2.0 (-3.5 to -0.5) |
| Systolic, 4-6 migraines per month | -3.3 (-7.0 to 0.4) |
| Systolic, >=4 migraines per month | -3.7 (-6.7 to -0.7) |
| Diastolic, <4 migraines per month | -1.2 (-2.5 to 0.00) |
| Diastolic, 4-6 migraines per month | -5.3 (-9.9 to -0.6) |
| Diastolic, >=4 migraines per month | -4.1 (-7.2 to -1.1) |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis.Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals were based on MMRM analysis.
| mmHg | Sumatriptan/Naproxen |
|---|---|
| Systolic, <1.3 doses per migraine | -0.3 (-2.7 to 2.0) |
| Systolic, 1.3-1.7 doses per migraine | -2.7 (-5.3 to -0.2) |
| Systolic, >1.7 doses per migraine | -3.8 (-6.2 to -1.5) |
| Diastolic, <1.3 doses per migraine | -0.4 (-2.2 to 1.5) |
| Diastolic, 1.3-1.7 doses per migraines | -0.9 (-2.9 to 1.2) |
| Diastolic, >1.7 doses per migraine | -3.2 (-5.3 to -1.0) |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 10-14 and the \>14 doses/month groups due to lack of convergence.
| mmHg | Sumatriptan/Naproxen |
|---|---|
| Systolic,<6 doses per month | -1.6 (-3.1 to 0.0) |
| Systolic, 6-10 doses per month | -4.6 (-7.4 to -1.8) |
| Systolic, >=6 doses per month | -4.3 (-7.1 to -1.6) |
| Diastolic,<6 doses per month | -1.0 (-2.2 to 0.3) |
| Diastolic, 6-10 doses per month | -3.7 (-7.1 to -0.4) |
| Diastolic, >=6 doses per month | -3.5 (-6.3 to -0.7) |
The calculation of baseline and post-baseline mean BP (either systolic or diastolic) for each month (30-day period) is the average of all valid T-SMBP measurements. The subgrouping of the ITT population was created and examined to demonstrate the robustness of the results for the primary analysis. Descriptive statistics were calculated for baseline, month 6, and change from baseline to month 6. LSMeans and corresponding confidence intervals (CIs) were based on MMRM analysis. LSMeans and CIs were not calculated for the 60-90 and the \>90 total dose groups due to lack of convergence.
| mmHg | Sumatriptan/Naproxen |
|---|---|
| Systolic, <30 total doses | -1.2 (-2.9 to 0.4) |
| Systolic, 30-60 total doses | -3.4 (-6.0 to -0.7) |
| Systolic, >=30 total doses | -3.7 (-6.0 to -1.4) |
| Diastolic, <30 total doses | -0.6 (-2.0 to 0.7) |
| Diastolic, 30-60 total doses | -3.3 (-5.8 to -0.8) |
| Diastolic, >=30 total doses | -3.6 (-5.7 to -1.4) |
The number of participants with an increase of \>=5 mmHg from the baseline systolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| participants | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Number of Participants With an Increase of >=5 mmHg From the Baseline Systolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements | 53 | 57 | 63 |
The number of participants with an increase of \>=3 mmHg from the baseline diastolic blood pressure for the average of any given two-day consecutive collection of valid blood pressure measurements during the study were summarized. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| participants | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Number of Participants With an Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure for the Average of Any Given Two-day Consecutive Collection of Blood Pressure Measurements | 72 | 65 | 77 |
The number of participants with any valid two-day consecutive average systolic blood pressure measurement of \>=140 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| participants | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Number of Participants With a Consecutive 2-day Average Systolic Blood Pressure of >=140 mmHg During the Study | 2 | 2 | 3 |
The number of participants with any valid two-day consecutive average diastolic blood pressure measurement of \>=90 mmHg was calculated. Valid blood pressure measurements were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| participants | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Number of Participants With a Consecutive 2-day Average Diastolic Blood Pressure of >=90 mmHg | 10 | 11 | 11 |
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| days | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Time to the First Day With an Average Systolic Blood Pressure Increase of >=5 mmHg From the Baseline Systolic Blood Pressure | 42.5 (2 to 177) | 32.5 (3 to 118) | 18.5 (3 to 124) |
Kaplan-Meier curves for the distribution of time to the first day with an average diastolic BP increase of \>=3 mmHg from the baseline diastolic BP during each calendar day were calculated and graphed for each treatment group. Only valid BP measurements were included and were defined as follows: must be taken at least 24 hours following last dose of investigational product used to treat an individual migraine, must be taken no later than 96 hours after last dose of investigational product used to treat an individual migraine, must be taken prior to the onset of a subsequent individual migraine.
| days | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Time to the First Day With an Average Diastolic Blood Pressure Increase of >=3 mmHg From the Baseline Diastolic Blood Pressure | 51 (2 to 140) | 50.5 (3 to 161) | 26 (3 to 124) |
The number of participants withdrawn from the study due to protocol-defined blood pressure changes were summarized for each treatment group. Defined blood pressure changes included (1) monthly average BP ≥140 mmHg systolic or \>=90 mmHg diastolic and confirmed in clinic, (2) monthly average BP increase of \>=30 mmHg systolic or \>=20 mmHg from in-clinic screening and confirmed in clinic, and (3) systolic \>=140 mmHg or diastolic \>=90 mmHg on consecutive clinic visits \>=2 weeks apart.
| participants | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Number of Participants Withdrawn From the Study Due to Blood Pressure Changes | 1 | 0 | 0 |
Collected over Serious adverse events (SAEs) and adverse events (AEs) were recorded from the start of investigational product and until any follow-up contact. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sumatriptan/Naproxen | — | 3/127 (2.4%) | 20/127 (15.7%) |
| Sumatriptan | — | 1/120 (0.8%) | 29/120 (24.2%) |
| Naproxen | — | 0/127 (0%) | 18/127 (14.2%) |
| Event | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| Abortion inducedPregnancy, puerperium and perinatal conditions | 0/127 | 1/120 | 0/127 |
| Chest painGeneral disorders | 1/127 | 0/120 | 0/127 |
| CellulitisInfections and infestations | 1/127 | 0/120 | 0/127 |
| ConvulsionNervous system disorders | 1/127 | 0/120 | 0/127 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/127 | 0/120 | 0/127 |
| Event | Sumatriptan/Naproxen | Sumatriptan | Naproxen |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/127 | 6/120 | 5/127 |
| Urinary tract infectionInfections and infestations | 1/127 | 6/120 | 3/127 |
| Upper respiratory tract infectionInfections and infestations | 0/127 | 5/120 | 1/127 |
| DizzinessNervous system disorders | 5/127 | 5/120 | 1/127 |
| Neck painMusculoskeletal and connective tissue disorders | 2/127 | 4/120 | 0/127 |
| NauseaGastrointestinal disorders | 4/127 | 2/120 | 1/127 |
| SomnolenceNervous system disorders | 2/127 | 3/120 | 2/127 |
| Back painMusculoskeletal and connective tissue disorders | 2/127 | 3/120 | 2/127 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/127 | 3/120 | 1/127 |
| SinusitisInfections and infestations | 3/127 | 2/120 | 1/127 |
| Age, Continuous(Years) | Sumatriptan/Naproxen | Sumatriptan | Naproxen | Total |
|---|---|---|---|---|
| Mean | 39.0 ± 11.64 | 39.8 ± 11.22 | 39.1 ± 11.92 | 39.3 ± 11.58 |
| Sex: Female, Male(Participants) | Sumatriptan/Naproxen | Sumatriptan | Naproxen | Total |
|---|---|---|---|---|
| Female | 94 | 98 | 96 | 288 |
| Male | 28 | 14 | 22 | 64 |
| Race/Ethnicity, Customized(participants) | Sumatriptan/Naproxen | Sumatriptan | Naproxen | Total |
|---|---|---|---|---|
| White | 108 | 96 | 105 | 309 |
| African American/African Heritage | 12 | 11 | 10 | 33 |
| Asian | 2 | 3 | 3 | 8 |
| Asian and White | 0 | 1 | 0 | 1 |
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Average Number of Migraine Attacks per Month(migraines) | Sumatriptan/Naproxen | Sumatriptan | Naproxen | Total |
|---|---|---|---|---|
| Mean | 4.5 ± 1.76 | 4.2 ± 1.67 | 4.6 ± 1.8 | 4.4 ± 1.75 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Nov 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year after primary completion. A results delay was requested in Aug 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.